CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Model construction and drug therapy of primary ovarian insufficiency by ultrasound-guided injection.
Model construction and drug therapy of primary ovarian insufficiency by ultrasound-guided injection.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
在我们的研究中,我们创新性地构建了超声引导下卵巢药物注射方法,以构建 POI-U 动物模型并注射 hUC-MSC 外泌体。我们证实了 hUC-MSC 外泌体对 POI-U 动物模型的治疗效果。我们的研究将为未来 POI 新动物模型提供更好的选择,并为 hUC-MSCs 外泌体治疗 POI 患者提供一定指导。
临床上,激素替代治疗(HRT)是原发性卵巢功能不全(POI)的主要治疗方法。然而,HRT可能增加乳腺癌和心血管疾病的风险。人脐带间充质干细胞(hUC-MSC)来源的外泌体通过抑制炎症、免疫调节和组织修复功能,已逐渐应用于多种疾病的治疗。然而,hUC-MSC外泌体在POI中的应用和研究仍然有限。
在此,我们首先构建了四种大鼠动物模型:POI-C模型(通过腹腔注射的“环磷酰胺诱导”POI模型)、POI-B模型(“白消安诱导”POI模型)、POI-U模型(超声引导下的“环磷酰胺诱导”POI模型)和MS模型(“母婴分离模型”)。其次,我们比较了不同POI大鼠模型的体重、卵巢指数、状态、大鼠面部表情量表、并发症和死亡率。最后,进行了经腹超声引导下注射hUC-MSC外泌体,并评估了其对POI动物模型的治疗作用,包括激素水平、动情周期、卵巢凋亡水平和生育能力的变化。此外,我们进行了RNA-seq以探索hUC-MSC外泌体功能的可能机制。
与 POI-C、POI-B 和 MS 动物模型相比,POI-U 模型体重波动更小、卵巢指数更低、并发症更少、死亡率更低、模型成功率更高。其次,我们成功鉴定了 hUC-MSCs 及其外泌体,并进行了超声引导下卵巢内 hUC-MSCs 外泌体注射。最后,我们证实超声引导下外泌体注射(称为 POI-e)有效改善了卵巢激素水平、动情周期、卵巢功能和生育能力。在机制上,hUC-MSCs 可能通过调节卵巢免疫和代谢功能发挥治疗作用。
Clinically, hormone replacement therapy (HRT) is the main treatment for primary ovarian insufficiency (POI). However, HRT may increase the risk of both breast cancer and cardiovascular disease. Exosomes derived from human umbilical cord mesenchymal stem cell (hUC-MSC) have been gradually applied to the therapy of a variety of diseases through inflammation inhibition, immune regulation, and tissue repair functions. However, the application and study of hUC-MSC exosomes in POI remain limited.
Here, we first constructed four rat animal models: the POI-C model (the "cyclophosphamide-induced" POI model via intraperitoneal injection), the POI-B model (the "busulfan-induced" POI model), the POI-U model (the "cyclophosphamide-induced" POI model under ultrasonic guidance), and MS model (the "maternal separation model"). Second, we compared the body weight, ovarian index, status, Rat Grimace Scale, complications, and mortality rate of different POI rat models. Finally, a transabdominal ultrasound-guided injection of hUC-MSC exosomes was performed, and its therapeuticy effects on the POI animal models were evaluated, including changes in hormone levels, oestrous cycles, ovarian apoptosis levels, and fertility. In addition, we performed RNA-seq to explore the possible mechanism of hUC-MSC exosomes function.
Compared with the POI-C, POI-B, and MS animal models, the POI-U model showed less fluctuation in weight, a lower ovarian index, fewer complications, a lower mortality rate, and a higher model success rate. Second, we successfully identified hUC-MSCs and their exosomes, and performed ultrasound-guided intraovarian hUC-MSCs exosomes injection. Finally, we confirmed that the ultrasound-guided exosome injection (termed POI-e) effectively improved ovarian hormone levels, the oestrous cycle, ovarian function, and fertility. Mechanically, hUC-MSCs may play a therapeutic role by regulating ovarian immune and metabolic functions.
In our study, we innovatively constructed an ultrasound-guided ovarian drug injection method to construct POI-U animal models and hUC-MSC exosomes injection. And we confirmed the therapeutic efficacy of hUC-MSC exosomes on the POI-U animal models. Our study will offer a better choice for new animal models of POI in the future and provides certain guidance for the hUC-MSCs exosome therapy in POI patients.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。